PROTARA THERAPEUTIC INC
TARANASDAQTrading Snapshot
- Day Range
- $3.16 – $3.23
- 52-Week Range
- $3.23 – $7.82
- Volume
- $2.46B
- Avg Volume
- $1.77B
- Shares Outstanding
- 56.2M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $4M
- P/E Ratio
- -2.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.15
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +74.2%
Why Investors Own TARA
- ✓High-growth profile — revenue up +34.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROTARA THERAPEUTIC INC
TARA
StockOtter · stockotter.spaceAbout PROTARA THERAPEUTIC INC
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that man
Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA
Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Com
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, de
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat reports. One equit
What Makes Protara Therapeutics (TARA) a New Buy Stock
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS
MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointment of Tara Bunch, former Senior Vice President and Global Head of Operations at Airbnb, to its Board of Directors. Bunch